一项评估IDCT(椎间盘内细胞疗法)在单节段、有症状的轻中度腰椎退行性椎间盘疾病受试者中有效性的研究 (IDCT)
一项前瞻性、随机、双盲、假对照、多中心研究,旨在评估IDCT对单节段、症状性轻度至中度腰椎间盘退行性变患者的安全性和有效性
This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration. The study will have a 52-week primary period followed by 52 week Follow-up Period (total of 104 weeks).
The study protocol will be approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), and the study will be conducted in accordance with Good Clinical Practice (GCP). All subjects will provide written informed consent prior to Screening.
Approximately 162 subjects will be enrolled in the study. Up to 45 days prior to treatment, subjects will be screened for study inclusion, which includes obtaining baseline MRI and X-ray imaging. Imaging results for subjects initially eligible for study participation will be sent to a central imaging vendor for review and confirmation of eligibility, including the number of levels with degeneration. Subjects meeting all inclusion/exclusion criteria will be assigned to the corresponding treatment arm group and subsequently randomized to IDCT or Sham.
Randomization will occur approximately 7 to 14 days prior to the scheduled treatment administration date.
Overall, 162 subjects will be enrolled and randomized to IDCT or Sham in a 2:1 ratio.
- IDCT (n=108)
- Sham (n=54)
研究概览
详细说明
Adult subjects with a diagnosis of single-level, mild to moderate, symptomatic lumbar (L3-S1) intervertebral disc degeneration that give consent and meet all the inclusion criteria and none of the exclusion criteria will be enrolled in this study. The disease, single-level disc will be known as the 'target disc' and will be either L3/L4, L4/L5, or L5/S1.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35235
- 招聘中
- Alabama Clinical Therapeutics
-
首席研究员:
- Brad 205-833-2228, MD
-
接触:
- Bailey Luster
- 电话号码:205-833-2228
- 邮箱:bailey.murphy@actstudy.net
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 招聘中
- Mayo Clinic (AZ)
-
首席研究员:
- John Freeman, MD
-
接触:
- Debbie Ryan
- 电话号码:480-342-1208
- 邮箱:Ryan.Debra29@mayo.edu
-
Scottsdale、Arizona、美国、85251
- 招聘中
- HonorHealth
-
首席研究员:
- Luis Tumialan, MD
-
接触:
- Helen Riahi
- 电话号码:602-258-2863
- 邮箱:hriahi@honorhealth.com
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205
- 招聘中
- University of Arkansas for Medical Sciences
-
接触:
- Lisa Richardson
- 电话号码:501-526-7664
- 邮箱:Lrichardson3@uams.edu
-
首席研究员:
- Erica Petersen, MD
-
-
California
-
San Diego、California、美国、92111
- 招聘中
- Solaris Research Institute
-
首席研究员:
- Krishnan Chakravarthy, MD
-
接触:
- Michelle Yi
- 电话号码:858-251-6420
- 邮箱:myi@solarisresearchinstitute.com
-
Santa Monica、California、美国、90403
- 招聘中
- Source Healthcare
-
首席研究员:
- Timothy Davis, MD
-
接触:
- Nidhi Thati
- 电话号码:310-574-2777
- 邮箱:nidhi@sourcehealthcare.com
-
Thousand Oaks、California、美国、91320
- 招聘中
- Pain Management and Injury Relief
-
接触:
- Yvonne Avila
- 电话号码:877-972-7576
- 邮箱:yvonne.avila@sclamanagement.com
-
首席研究员:
- Alexander Hersel, MD
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20006
- 招聘中
- International Spine, Pain and Performance Center
-
首席研究员:
- Mehul Desai, MD
-
接触:
- Sydney Sheridan
- 电话号码:202-808-8295
- 邮箱:ssheridan@isppcenter.com
-
-
Florida
-
Jacksonville、Florida、美国、32224
- 招聘中
- Mayo Clinic (FL)
-
接触:
- Katie Siebenlar
- 电话号码:904-953-4915
- 邮箱:siebenaler.katie@mayo.edu
-
首席研究员:
- Wenchun Qu, MD
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami Health System
-
接触:
- Yamilet Nieves Nieves
- 电话号码:305-243-3048
- 邮箱:yxn176@med.miami.edu
-
首席研究员:
- Barth Green, MD
-
Orlando、Florida、美国、32832
- 招聘中
- Conquest Research
-
首席研究员:
- Gilbert Mbeo, MD
-
接触:
- Kendra Tandeski
- 电话号码:689-488-9112
- 邮箱:kendra.tandeski@conquestresearch.com
-
St. Petersburg、Florida、美国、33709
- 招聘中
- Vantage Clinical Trials
-
首席研究员:
- Robert Guirguis, MD
-
接触:
- Civahn Robinson
- 电话号码:727-471-6226
- 邮箱:crobinson@vantagetrials.com
-
Tampa、Florida、美国、33709
- 招聘中
- Vantage Clinical Trials
-
首席研究员:
- Jorge Leal, MD
-
接触:
- Yiset Sanchez
- 电话号码:813-549-5262
- 邮箱:ysanchez@vantagetrials.com
-
-
Idaho
-
Boise、Idaho、美国、83709
- 终止
- Injury Care Family Care Research
-
Post Falls、Idaho、美国、83854
- 招聘中
- Axis Spine Center
-
首席研究员:
- Jessica Jameson, MD
-
接触:
- Study Coordinator
- 电话号码:208-457-4208
- 邮箱:elisa.maples@nwsh.com
-
接触:
-
-
Illinois
-
Chicago、Illinois、美国、60612
- 招聘中
- Rush University Medical Center
-
首席研究员:
- John O'Toole, MD
-
接触:
- Reehan Malhance
- 电话号码:312.942.0512
- 邮箱:Reehan_T_Malhance@rush.edu
-
-
Indiana
-
Carmel、Indiana、美国、46032
- 招聘中
- Indiana Spine Group
-
接触:
- Sheetal Vinayek
- 电话号码:317-715-5897
- 邮箱:svinayek@indianaspinegroup.com
-
首席研究员:
- Kevin Macadaeg, MD
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- 招聘中
- Norton Leatherman Spine Center
-
接触:
- Morgan Brown
- 电话号码:502-584-7525
- 邮箱:morgan.brown2@nortonhealthcare.org
-
首席研究员:
- Steven Glassman, MD
-
-
Louisiana
-
New Orleans、Louisiana、美国、70121
- 招聘中
- Ochsner Health System
-
首席研究员:
- Maged Guirguis, MD
-
接触:
- Raquel Walker
- 电话号码:504-703-6091
- 邮箱:raquel.walker@ochsner.org
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic (MN)
-
首席研究员:
- Ryan D'Souza, MD
-
接触:
- Rose Decker
- 电话号码:507-422-0584
- 邮箱:decker.rose@mayo.edu
-
-
Missouri
-
St Louis、Missouri、美国、63141
- 招聘中
- The Orthopedic Center of St. Louis
-
接触:
- Study Coordinator
- 电话号码:314-738-4822
- 邮箱:fschranck@spirittresearch.com
-
首席研究员:
- Matthew Gornet, MD
-
-
New York
-
New York、New York、美国、10022
- 招聘中
- Weill Cornell Medicine for Comprehensive Spine Care
-
接触:
- Jeffery Tan
- 电话号码:888-922-2257
- 邮箱:jet4014@med.cornell.edu
-
首席研究员:
- Prabhav Deo, MD
-
-
North Carolina
-
Wilmington、North Carolina、美国、28403
- 招聘中
- Wake Research
-
首席研究员:
- Jeremy Hoff, MD
-
接触:
- Study Coordinator
- 电话号码:919-645-9212
- 邮箱:dmyers@wakeresearch.com
-
Winston-Salem、North Carolina、美国、27103
- 招聘中
- Carolinas Pain Institute/ Center For Clinical Research
-
首席研究员:
- Christopher Gilmore, MD
-
接触:
- Study Coordinator
- 电话号码:ext 146 336-765-6181
- 邮箱:jbrewer@ccrpain.com
-
-
Ohio
-
Cleveland、Ohio、美国、10524
- 招聘中
- Cleveland Clinic
-
接触:
- Heather Rogers
- 电话号码:216-444-1292
- 邮箱:ROGERSH3@ccf.org
-
首席研究员:
- Jijun Xu, MD
-
-
Oregon
-
Eugene、Oregon、美国、97404
- 招聘中
- Pacific Sports and Spine
-
首席研究员:
- Gregory Moore, MD
-
接触:
- Ashley Hamann
- 电话号码:541-780-0355
- 邮箱:ahamann@pacificsportsandspine.com
-
-
Pennsylvania
-
King of Prussia、Pennsylvania、美国、19406
- 招聘中
- Main Line Spine
-
首席研究员:
- Scott Davidoff, MD
-
接触:
- Cheryl Pugh
- 电话号码:610-337-3111
- 邮箱:cherylp@mainlinespine.com
-
-
Tennessee
-
Memphis、Tennessee、美国、38120
- 招聘中
- Semmes Murphey Neurological Clinic
-
接触:
- 电话号码:901-259-5319
- 邮箱:jarnold@semmes-murphey.com
-
首席研究员:
- Michael LaBagnara, MD
-
接触:
- Study Coordinator
- 电话号码:901-260-6111
- 邮箱:cberryman@semmes-murphey.com
-
-
Texas
-
Austin、Texas、美国、78745
- 招聘中
- Pain Specialists of America
-
首席研究员:
- Genaro Gutierrez, MD
-
接触:
- Sheila Nardelli
- 电话号码:949-922-5785
- 邮箱:sheila@researchtex.com
-
-
Utah
-
Salt Lake City、Utah、美国、84108
- 招聘中
- University of Utah
-
首席研究员:
- Zachary McCormick, MD
-
接触:
- Tou Xiong
- 电话号码:801-587-5341
- 邮箱:Tou.Xiong@hsc.utah.edu
-
-
Virginia
-
Richmond、Virginia、美国、23238
- 招聘中
- Virginia iSpine Physicians
-
首席研究员:
- Michael DePalma, MD
-
接触:
- Devon Withers
- 电话号码:804-330-2611
- 邮箱:crc2@vaispine.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Has a diagnosis of mild to moderate, symptomatic, single-level degenerative disc disease (DDD) from L3-S1.
-
Has a target disc that meets Modified Pfirrmann Grade 3-7, as determined by a central radiologist.
-
Is ≥18 and ≤75 years of age, skeletally mature, and has a body mass index (BMI) ≥18 kg/m2 and ≤38 kg/m2 at Screening.
-
Has been experiencing chronic low back pain for at least 6 months prior to Screening.
-
Has had low back pain that is unresponsive to at least 3 months of conservative care (nonoperative treatment) to include at least one non-pharmacological intervention which may include physical therapy, acupuncture, chiropractic manipulation, massage, and at home medically supervised exercise program and two pharmacological interventions which may include NSAIDs, acetaminophen, duloxetine, and/or injectable therapy.
-
Has pre-treatment low back pain score of 45 to 90 on VAS (Visual Analogue Scale) for low back pain at Screening and Day 1.
-
Has pre-treatment ODI score of 35 to 90 at Screening and Day 1.
-
Is willing to voluntarily sign the informed consent form and agrees to the release of previous medical history for purposes of this study (i.e., HIPAA authorization) at Screening.
-
Is physically and mentally able to comply with the protocol, able to understand and complete the required forms, and willing and able to adhere to the requirements of the protocol in the opinion of the Investigator.
-
Female-born subjects of childbearing potential must agree to and comply with using highly effective methods of birth control for the duration of the study (e.g., oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, condoms, or a vasectomized partner).-
Exclusion Criteria:
Physical/ Medical History Exclusion Criteria
-
Has low back pain that in the Investigator's opinion is predominately myofascial in nature.
-
Has constant, unchanging low back pain that is not improved in any spinal position.
-
Has radiculopathy resulting from nerve compression.
-
Has non-radicular unilateral or bilateral leg pain with intensity greater than 50% of the intensity of the low-back pain, as measured by VAS.
-
Leg pain that is of radicular origin, i.e., due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces.
-
Has frequent leg pain that extends below the knee.
-
Has severe unilateral or bilateral osteoarthritis of the knee or hip.
-
Severe spinal arthritis
-
Has cauda equina syndrome.
-
Has had previous lumbar spine surgery.
-
Has had previous disc invasive treatment procedures (i.e., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) or intradiscal injections (i.e., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate) or diagnostic discography at L3-S1 within the 3 months prior to Screening.
-
Subjects who have had basivertebral nerve ablation at L3-S1.
-
Has clinical suspicion of facet pain as the primary pain generator.
-
Has current infection at the planned procedure site, active systemic infection, or current or prior history of lumbar spinal infection (i.e., discitis, septic arthritis, epidural abscess).
-
Has a history of fibromyalgia.
-
Has tested positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human Immunodeficiency Virus (HIV).
-
Has presence of an active malignancy or tumor, or a prior history of malignancy within the last five years (except for basal cell carcinoma of the skin).
-
Has presence or prior history of a spinal malignancy.
-
Has significant systemic disease, such as unstable angina or autoimmune disease, such as rheumatoid arthritis. Has a history of congenital or acquired coagulopathy or thrombocytopenia.
31. Is currently taking anticoagulant, antiplatelet, or thrombolytic medications (except for aspirin or nonsteroidal anti-inflammatory drugs [NSAIDS]) and at the Investigator's medical discernment and discretion is unable to withhold medications for the time required per site standard or care, prior to the IDCT injection or is taking antineoplastic medications.
32. Is at higher risk for post-surgical infection (e.g., taking immunosuppressants), has a severe infection or a history of serious infection.
33. Has concomitant conditions requiring daily oral steroid usage for more than 30 days in the preceding 90 days before Screening.
34. Is taking opioids greater than 20 MME per day on an intermittent (as needed) basis OR is taking 20 MME or greater daily for more than 3 months prior to Screening
35. Has a history of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.
36. Has a history of hypersensitivity or anaphylactic reaction to bovine products, sodium hyaluronate/ hyaluronan/ hyaluronic acid, gentamicin, amphotericin b, dimethyl sulfoxide (DMSO), crustaceous/ shellfish, or porcine products.
37. Has an uncontrolled psychiatric condition or substance/alcohol abuse that would potentially interfere with the subject's participation in the study within 2 years prior to Screening in the opinion of the Investigator.
38. Has positive serum pregnancy test or nursing at time of Screening or has plans to become pregnant within the planned length of the study (2 years).
39. Has a body habitus that precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible.
40. Has or requires an implantable electronic defibrillator, pacemaker, or has other contraindication to MRI scanning or cannot tolerate MRI scanning. Subjects who are expected to require a defibrillator or pacemaker, as determined by the Investigator should be excluded.
41. Has participated in another clinical study within the 6 months prior to Screening.
42. Has been a recipient or plans to be a recipient during trial participation of stem cell product to treat the lumbar spine.
43. Has participated in a prior IDCT clinical study.
44. Has pending litigation against a health care professional, except where required by the insurer as a condition of coverage.
45. A person who would not be available for the entire planned length of the trial.
46. Has active or pending worker's compensation claims. 47. In the Investigators opinion, the subject is not suitable for participation in the clinical trial.
Imaging Exclusion Criteria:
48. Three discs (L3-S1) that have a Modified Pfirrmann Grade 4-7.
49. Has evidence of prior lumbar vertebral body fracture at L3-S1.
50. Has scoliosis with curvature > 10 degrees.
51. Has congenital spinal irregularities such as segmentation.
52. Has an acute fracture of the spine at the time of enrollment in the study. Clinically compromised vertebral bodies within L3-S1 due to current or past trauma, e.g., sustained pathological fracture or multiple fractures of vertebrae.
53. Has evidence of dynamic instability on lumbar flexion extension per screening radiographs as indicated by >4.5 mm of translational motion at L3-S1; >15° of angular motion at L3/-L4; >20° of angular motion at L4-L/5; or >25° angular motion at L5/-S1.
54. Has Grade 2 or higher spondylolisthesis at L3-S1, as assessed by Meyerding classification.
55. Has lumbar spondylitis or other undifferentiated spondyloarthropathy.
56. Has Modic Type III Changes at L3-S1.
57. Has radiographic evidence or suspicion of a full thickness annular tear at L3-S1.
58. Has evidence of abnormal disc morphology defined as an extrusion or sequestration according to Fardon classification at L3- S1.
59. Has herniation > 3 mm in AP dimension that is associated with nerve root compression.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:IDCT (n=108); Intradiscal injection of IDCT in a single target disc
1 mL intradiscal injection of 9,000,000 cells/mL |
Single intradiscal injection of 1 mL of 9,000,000 cells/mL IDCT in a single target disc. |
|
假比较器:Sham (n=54);
Needle insertion up to the annulus of a single target disc. |
Single Sham needle insertion up to the annulus of a single target disc. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Visual Analogue Scale (VAS) for low back pain
大体时间:Week 52
|
VAS is a sliding visual scale of 0 being "no pain" and 100 being "worst pain Imaginable' to assess changesfrom baseline in low back pain compared to Sham |
Week 52
|
|
Oswestry Disability Index (ODI)
大体时间:Week 52
|
ODI is a 10-item questionnaire used to measure functional disability in people with low back pain. It is a self-administered tool that assesses how back pain affects daily activities like walking, sleeping, and personal hygiene, with scores ranging from 0% (no disability) to 100% (maximum disability). |
Week 52
|
|
Adverse Events
大体时间:Day 1 to Week 52 in each treatment group.
|
Incidence of grade 2 (moderate) or greater AEs and SAEs |
Day 1 to Week 52 in each treatment group.
|
|
Adverse events of special interest
大体时间:Day 1 to Week 52 in each treatment group
|
Incidence of Adverse Events of Special Interest (AESI) to include any symptomatic injury of the target disc including annular tear, disc herniation/extrusion/prolapse as well as discitis. |
Day 1 to Week 52 in each treatment group
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Visual Analogue Scale (VAS)
大体时间:Week 4, 12 and 26, 78 and 104
|
VAS is a sliding visual scale of 0 being "no pain" and 100 being "worst pain Imaginable' to assess changes from baseline in low back pain |
Week 4, 12 and 26, 78 and 104
|
|
Oswestry Disability Index (ODI)
大体时间:Week 4, 12 and 26, 78 and 105
|
ODI is a 10-item questionnaire used to measure functional disability in people with low back pain. It is a self-administered tool that assesses how back pain affects daily activities like walking, sleeping, and personal hygiene, with scores ranging from 0% (no disability) to 100% (maximum disability). |
Week 4, 12 and 26, 78 and 105
|
|
EQ-5D
大体时间:Enrollment through Week 104
|
EQ-5D is a validated too consisting of a set of questions covering five dimensions, with each dimension having a different severity level.
|
Enrollment through Week 104
|
|
Disc Volume
大体时间:Day 1 to Week 104
|
MRI assessment of Disc Volume though Week 104 |
Day 1 to Week 104
|
|
Pain Medication Use
大体时间:Enrollment to Week 104
|
Concomitant pain medication use for low back pain related to the target disc |
Enrollment to Week 104
|
|
Concomitant Therapy
大体时间:Enrollment to Week 104
|
Concomitant medical therapy for low back pain (physical therapy, acupuncture, chiropractic manipulation, massage, and at-home, medically supervised exercise program etc.) use for low back pain |
Enrollment to Week 104
|
|
Treatment Failure Rate
大体时间:Enrollment to week 104
|
Treatment failure rate (defined as an invasive non-surgical or surgical intervention) directly related to the target disc. |
Enrollment to week 104
|
|
Adverse Events
大体时间:Enrollment to Week 104
|
The incidence of grade 2 (moderate) or greater AEs and SAEs |
Enrollment to Week 104
|
|
Adverse Events of Special Interest (AESI)
大体时间:Enrollment to Week 104
|
The incidence of Adverse Events of Special Interest (AESI) observed defined as any one of the followings symptomatic injury of the target disc including annular tear, disc, herniation/extrusion/prolapse or any case of discitis. |
Enrollment to Week 104
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
MRI Based evaluations
大体时间:Enrollment through Week 104
|
MRI Evaluation of the lumbar spine will be reported as an aggregate in one report to assess of disc height, Modified Pfirrmann grade, Modic changes, annular tears/fissures, endplate integrity, herniation, and any additional noteworthy observations at 12, 26, 52, 78, and 104. |
Enrollment through Week 104
|
|
X-ray evaluation of the lumbar spine
大体时间:Screening through Week 104
|
X-ray evaluation of flexion/extension will be assessed and measure in degrees of angles. |
Screening through Week 104
|
合作者和调查者
调查人员
- 研究主任:Lisa Flood、DiscGenics, Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.